Acorda Therapeutics’ CVT-301 Data Will Be Featured at American Academy of Neurology


(April 8, 2016) - Acorda Therapeutics, Inc. today announced that data from a Phase 2b clinical trial of CVT-301 in Parkinson’s disease (PD) will be featured during the Movement Disorders Invited Science Session at the upcoming 68th Annual Meeting of the American Academy of Neurology, being held in Vancouver, Canada. Invited Science Sessions are intended to highlight cutting-edge research in selected therapeutic categories. Read more…

Click for a printer friendly version

Back to top